Digestive Disease Week® (DDW) is one of the largest meetings for the GI professional and attracts 15,000 physicians, researchers and academicians each year. At DDW you'll learn about new developments in your field, attend high-quality educational programs and network with colleagues.
The AASLD Meeting at DDW provides a forum for the exchange of groundbreaking research and clinical information in diseases of the liver and biliary tract and in liver transplantation. This will be done in a variety of formats, including plenary and parallel sessions, courses, workshops and state-of-the-art lectures.
DDW is co-sponsored by AASLD, AGA, ASGE and SSAT. It will be held at the San Diego Convention Center in San Diego, CA.
The 2019 abstract submission site closed at 9 pm ET on December 1, 2018.
AASLD's headquarter hotel is the Manchester Grand Hyatt. Make your reservation through DDW's official housing block.
To learn about AASLD and other programming, see the tabs below or visit the DDW Online Planner.
This symposium will provide a succinct but comprehensive update on clinical advances in the management of liver disease. The practice of hepatology continues to evolve as HCV has diminished as an indication for consultation while other diseases assume increasing prominence, including hepatocellular carcinoma. The program will update attendees on current and future treatment options for viral and nonviral liver disease as well as other aspects of liver disease, including portal hypertension and hepatocellular carcinoma.
Safe and highly effective antivirals (peginterferon, entecavir, tenofovir) are available for HBV but these therapies infrequently achieve HBsAg loss. New therapeutic approaches are focused on achieving HBsAg loss and/or sustained suppression of HBV DNA off treatment. Withdrawal of nucleos(t)ide analogues after defined periods of viral suppression is one strategy being studied. Additionally, multiple new HBV drugs targeting alternative steps in the viral life cycle or host immune responses are in development and provide hope for a future HBV cure.
As liver transplantation (LT) has become part of the standard armamentarium in tertiary care centers, the boundaries for selection of candidates have enlarged gradually. This session will focus on three persistent boundary limits that continue to apply: advanced age, addiction to alcohol, and in the case of hepatic tumors, tumor burden. It will use these examples to explore the dynamics of selection for and outcome of LT.
This will be a state-of-the-art lecture to review the current understanding of liver injury due to drugs and dietary supplements. The lecture will cover early recognition, accurate diagnosis and clinical management. There will be a focus on agents commonly implicated in liver injury, both conventional medications and herbal and dietary supplements.
Hepatocellular carcinoma is rising in incidence and mortality. Liver transplant offers the best chance for long term survival, but many patients are diagnosed at an advanced stage that often precludes surgery. Advancements in both locoregional therapy and systemic options have demonstrated improvements in survival but may be limited to those with preserved liver function. Continued work is needed to identify those at risk for HCC so surveillance can be initiated and diagnosis made at a curative state. Additionally, improved prognostic models and use of bio markers is crucial to personalize the treatment approach to HCC.
Liver masses have been a common reason for consultation faced by gastroenterologists, hepatologists, and transplant/hepatobiliary surgeons. The increasing and widespread use of cross-sectional imaging studies has led to an increase in detection of liver masses. It is important to consider not only malignant liver lesions, but also benign solid and cystic liver lesions. This symposium will help participants understand the diagnostic criteria of liver masses, and the management of benign and malignant liver masses.
This symposium will summarize available pre-clinical data on the role of gut microbiome and NAFLD, human clinical data that demonstrate an association between gut microbiome in human NASH and progression of fibrosis, and the role of gut microbiome in its association with hepatocellular carcinoma.
Patients with decompensated cirrhosis are known to have very high rates of hospitalization – and up to one-third experience re-admission within 30 days after discharge. Hospitals and physician groups are under increasing financial pressure to prevent these hospitalizations. This symposium will provide an overview of the problem, identify risk factors for hospitalization, and provide evidence-based interventions. Finally, we will discuss novel approaches and provide a guide to implementation.
Bleeding related to portal hypertension remains a major life-threatening clinical event among patients with cirrhosis. Strategies had been directed at preventing/treating variceal hemorrhage. This symposium will focus on risk stratification (using invasive and noninvasive tools) that will identify patients who will be more (or less) likely to benefit from certain therapies, vis-à-vis not only variceal hemorrhage but also the prevention/treatment of other complications of cirrhosis. These strategies will be discussed in a case-based setting that will help participants understand the current concepts regarding risk stratification and therapies for portal hypertension/varices at different stages of cirrhosis.
Urgent management of liver failure is challenging and the first few days can make a major difference in the prognosis. This symposium will focus on the differentiation and early management of acute liver failure versus acute-on-chronic liver failure. Cutting edge prognostication and therapeutic options, including liver transplant candidacy and outcomes will also be discussed.
Although viral hepatitis has incredibly effective therapy, disruption of maternal to child transmission (MTCT) remains an important aspect of prevention. Management of any liver disease during pregnancy is a balance between risk of therapy and benefit to both the mother and the child. This case based symposium will help participants understand and modify these challenging clinical choices.